AstraZeneca: FDA Approves Imfinzi Plus Chemotherapy To Treat Biliary Tract Cancer

British drug major AstraZeneca Plc. (AZN.L, AZN) announced Monday that the U.S. Food and Drug Administration has approved Imfinzi (durvalumab) as the first immunotherapy regimen for patients with advanced biliary tract cancer or BTC.